Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., explained in plain language.
-
New drug cocktail aims to stop triple negative breast cancer from returning
Disease control Not yet recruitingThis Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New drug combo aims to outperform standard therapy for advanced colorectal cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the ne…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug SHR-5421 takes on Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis early-phase trial is testing a new drug, SHR-5421, in about 97 people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for bladder cancer patients: experimental drug combo aims to beat chemo
Disease control Not yet recruitingThis Phase 3 trial is testing whether a combination of an experimental drug (SHR-1501) plus the standard immunotherapy BCG works better than chemotherapy for people with a type of bladder cancer (papillary-only NMIBC) that no longer responds to BCG alone. The study plans to enrol…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug SHR-4298 enters early human testing
Disease control Not yet recruitingThis study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC